Bone marrow-derived endothelial progenitor cells: isolation and characterization for myocardial repair.
Vascular regeneration with bone marrow (BM) stem/progenitor cells is one of the promising therapeutic strategies for myocardial repair in cardiovascular diseases. Endothelial progenitor cells (EPCs) have demonstrated the beneficial effects on ischemia-induced myocardial damage promoting angiogenesis in ischemic tissue. Isolation of EPCs from BM or peripheral blood is required for the cell-based therapeutic approach. Among a variety of EPC isolation methods, specifically in the case of experimental animal models, we have shown our recently developed mouse-cultured EPC isolation protocol, which is viable for obtaining enough number of viable cells for not only in vitro but also in vivo experiments, and the protocol for human CD34(+) cell (EPC rich cell population) isolation from peripheral blood and characterization by fluorescence-activated sorting (FACS) system.
Ii
Masaaki
M
Group of Vascular Regeneration Research, Institute of Biomedical Research and Innovation, Minatojima-minamimachi, Chuo-ku, Kobe, Japan. masa0331@mac.com
D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D001854:Bone Marrow Cells / Q000166:cytology*; D064987:Cell- and Tissue-Based Therapy; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000166:cytology*; D005434:Flow Cytometry; D006801:Humans; D051379:Mice; D017202:Myocardial Ischemia / Q000378:metabolism / Q000628:therapy; D009206:Myocardium / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000502:physiology; D013234:Stem Cells / Q000166:cytology* / Q000502:physiology
D018952:Antigens, CD34